A R T I C L E S
Turnbull et al.
Figure 1. Composite structure of gangliosides used in binding studies with CTB.
structures of the bound and free proteins reveals that there is
only a small change to the backbone conformation (albeit mostly
18
around the galactose binding site) on complexation. Further-
1
9
more, solution structures of GM1os indicate that the ligand is
essentially preorganized for a near lock-and-key interaction with
CTB.
Considering the importance of this interaction to the progres-
sion of cholera (and traveler’s diarrhea in the case of the E.
coli heat-labile toxin), it is not surprising that there have been
several studies reported on the selectivity and structural basis
of complexation for GM1 and analogous ligands. Techniques
3
,20
as broad ranging as solid-phase and TLC overlay assays,
2
1,22
surface plasmon resonance (SPR) biosensing,
fluorescence
and flow cytometry (FACS), atomic force
microscopy (AFM), and isothermal titration calorimetry
ITC) have been applied to the problems of deconvoluting
the kinetics and thermodynamics of this multivalent interaction
and to rationalize the exquisite binding selectivity for GM1.
The general trend in binding affinities/avidities that emerges
2
3,24
9
spectroscopy
2
5
2
6
(
Figure 2. Schematic representation of the CTB-GM1os complex after
Merritt et al., ref 14.
from these studies is GM1 ≈ FucGM1 > GD1b . GM2 >
gaining further insight into the factors governing affinity and
selectivity in protein-carbohydrate interactions.
3,20,22,26,27
GA1 > GM3 (Figure 1).
Structure-activity relation-
ship studies of the sialic acid functional groups indicate that
loss of the negative charge has a greater influence on affinity
than removal/alteration of the acetamide group or glycerol side
The crystal structure of the CTB-GM1os complex has been
refined to 1.25 Å resolution.1 It shows a bivalent interaction
of the branched GM1os pentasaccharide, which has been likened
to the carbohydrate holding the protein in a “two-fingered grip”
comprising a sialic acid thumb and a Galâ(1f3)GalNAc
forefinger (Figure 2). There are extensive intermolecular hydro-
gen-bonding contacts, both directly between the ligand and
receptor and also via bridging water molecules. In terms of
buried surface area, the terminal Gal, GalNAc, and Neu5Ac
residues contribute 39%, 17%, and 43% of the intermolecular
4,15
2
8
chain.
However, it is more difficult to extract precise information
on the intrinsic contribution of each monosaccharide residue in
the GM1 ligand from experiments conducted under multivalent
conditions, as the mode of presentation of the ligand groups
2
9
can strongly affect experimental results, even giving quite
2
1,22
conflicting views of intrinsic selectivities.
Therefore, to try
1
4
(18) (a) Merritt, E. A.; Sixma, T. K.; Kalk, K. H.; van Zanten, B. A. M.; Hol,
W. G. J. Mol. Microbiol. 1994, 13, 745-753. (b) Zhang, R. G.; Westbrook,
M. L.; Westbrook, E. M.; Scott, D. L.; Otwinowski, Z.; Maulik, P. R.;
Reed, R. A.; Shipley, G. G. J. Mol. Biol. 1995, 251, 550-562.
contacts. A large number of crystal structures of complexes
between galactose derivatives and CTB or LTB have also been
reported,11,16
17
including that of the Tn antigen, which represents
(
19) (a) Acquotti, D.; Poppe, L.; Dabrowski, J.; Vonderlieth, C. W.; Sonnino,
S.; Tettamanti, G. J. Am. Chem. Soc. 1990, 112, 7772-7778. (b)
Richardson, J. M.; Milton, M. J.; Homans, S. W. J. Mol. Recog. 1995, 8,
the Galâ(1f3)GalNAc forefinger of GM1os. In all such
complexes, the orientation of galactose and the structure of the
binding site are essentially identical. Comparison of the
3
58-362. (c) Brocca, P.; Berthault, P.; Sonnino, S. Biophys. J. 1998, 74,
309-318. (d) Brocca, P.; Bernardi, A.; Raimondi, L.; Sonnino, S.
Glycoconjugate J. 2001, 17, 283-299.
(20) Ångstr o¨ m, J.; Teneberg, S.; Karlsson, K.-A. Proc. Natl. Acad. Sci. U.S.A.
1994, 91, 11859-11863.
(
13) (a) Thompson, J. P.; Schengrund, C.-L. Biochem. Pharm. 1998, 56, 591-
5
97. (b) Vrasidas, I.; de Mol, N. J.; Liskamp, R. M. J.; Pieters, R. J. Eur.
(21) Kuziemko, G. M.; Stroh, M.; Stevens, R. C. Biochemistry 1996, 35, 6375-
6384.
J. Org. Chem. 2001, 4685-4692. (c) Merritt, E. A.; Zhang, Z.; Pickens, J.
C.; Ahn, M.; Hol, W. G. J.; Fan, E. J. Am. Chem. Soc. 2002, 124, 8818-
(22) MacKenzie, C. R.; Hirama, T.; Lee, K. K.; Altman, E.; Young, N. M. J.
Biol. Chem. 1997, 272, 5533-5538.
8
824. (d) Zhang, Z.; Merritt, E. A.; Ahn, M.; Roach, C.; Hou, Z.; Verlinde,
C. L. M. J.; Hol, W. G. J.; Fan, E. J. Am. Chem. Soc. 2002, 124, 12991-
(23) Picking, W. L.; Moon, H.; Wu, H.; Picking, W. D. Biochim. Biophys. Acta
1995, 1247, 65-73.
1
2998. (e) Schengrund, C. L. Biochem. Pharm. 2003, 65, 699-707.
(
(
(
14) Merritt, E. A.; Sarfaty, S.; van den Akker, F.; L’Hoir, C. L.; Martial, J. A.;
(24) Mertz, J. A.; McCann, J. A.; Picking, W. D. Biochem. Biophys. Res.
Commun. 1996, 226, 140-144.
Hol, W. G. J. Protein Sci. 1994, 3, 166-175.
15) Merritt, E. A.; Kuhn, P.; Sarfaty, S.; Erbe, J. L.; Holmes, R. K.; Hol, W.
G. J. J. Mol. Biol. 1998, 282, 1043-1059.
16) (a) Merritt, E. A.; Sarfaty, S.; Feil, I. K.; Hol, W. G. J. Structure 1997, 5,
(25) Cai, X.-E.; Yang, J. Biochemistry 2003, 42, 4028-4034.
(26) Masserini, M.; Freire, E.; Palestini, P.; Calappi, E.; Tettamanti, G.
Biochemistry 1992, 31, 2422-2426.
1
485-1499. (b) Fan, E.; Merritt, E. A.; Zhang, Z.; Pickens, J. C.; Roach,
(27) Schengrund, C. L.; Ringler, N. J. J. Biol. Chem. 1989, 264, 13233-13237.
(28) (a) Lanne, B.; Schierbeck, B.; Karlsson, K.-A. J. Biochem. (Tokyo) 1994,
116, 1269-1274. (b) Lanne, B.; Schierbeck, B.; Angstrom, J. J. Biochem.
(Tokyo) 1999, 126, 226-234.
C.; Ahn, M.; Hol, W. G. J. Acta Crystallogr., D 2001, D57, 201-212.
17) van den Akker, F.; Steensma, E.; Hol, W. G. J. Protein Sci. 1996, 5, 1184-
(
1
188.
1048 J. AM. CHEM. SOC.
9
VOL. 126, NO. 4, 2004